Mersana Therapeutics, Inc.
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clin…
Biotechnology
US, Cambridge [HQ]
Risk Factors
By Management
Not Available
No Risk Factor available yet. You can request "Risk Factors" through an email.